Technical Analysis for SPRB - Spruce Biosciences, Inc.
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Weak or Absent | N/A | N/A | Up |
| Historical SPRB trend table... | |||
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| Spinning Top | Other | 3.15% | |
| Outside Day | Range Expansion | 3.15% | |
| Up 3 Days in a Row | Strength | 0.24% | |
| Inside Day | Range Contraction | 1.25% | |
| Hot IPO Pullback | Bullish Swing Setup | 4.74% | |
| Inside Day | Range Contraction | 4.74% | |
| New 52 Week Closing Low | Bearish | 10.66% | |
| Hot IPO Pullback | Bullish Swing Setup | 10.66% | |
| New 52 Week Closing Low | Bearish | 2.53% | |
| Hot IPO Pullback | Bullish Swing Setup | 2.53% |
Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App
| Alert | Time | |
|---|---|---|
| Up 5% | 2 days ago | |
| Rose Above Previous Day's High | 3 days ago | |
| Up 3% | 3 days ago | |
| Up 2% | 3 days ago | |
| 60 Minute Opening Range Breakout | 3 days ago |
Free Daily (Stock) Chart Reading
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Configure default chart indicators
Basic chart:
- Earnings date: ???
- Sector: Healthcare
- Industry: Biotechnology
Spruce Biosciences, Inc., a biopharmaceutical company, focuses on developing and commercializing novel therapies for rare endocrine disorders. The company develops tildacerfont, an non-steroidal therapy, which is in Phase IIb clinical trial for adult patients with classic congenital adrenal hyperplasia (CAH) and in Phase II clinical trial in children with classic CAH. It is also developing tildacerfont for females with polycystic ovary syndrome. The company has a license agreement with Eli Lilly and Company to research, develop, and commercialize compounds for various pharmaceutical uses. Spruce Biosciences, Inc. was founded in 2014 and is headquartered in Daly City, California.
Medicine Biopharmaceutical Anatomy Adrenal Gland Disorders Congenital Adrenal Hyperplasia Hyperplasia Classic Congenital Adrenal Hyperplasia Neurocrine Biosciences
Medicine Biopharmaceutical Anatomy Adrenal Gland Disorders Congenital Adrenal Hyperplasia Hyperplasia Classic Congenital Adrenal Hyperplasia Neurocrine Biosciences
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 18.4894 |
| 52 Week Low | 15.14 |
| Average Volume | 144,273 |
| 200-Day Moving Average | 0.00 |
| 50-Day Moving Average | 0.00 |
| 20-Day Moving Average | 0.00 |
| 10-Day Moving Average | 16.78 |
| Average True Range | 0.00 |
| ADX | 0.0 |
| +DI | 0.00 |
| -DI | 0.00 |
| Chandelier Exit (Long, 3 ATRs ) | N/A |
| Chandelier Exit (Short, 3 ATRs ) | N/A |
| Upper Bollinger Band | 0.00 |
| Lower Bollinger Band | 0.00 |
| Percent B (%b) | 0.0 |
| BandWidth | 0.00 |
| MACD Line | 0.00 |
| MACD Signal Line | 0.00 |
| MACD Histogram | 0.0 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 18.60 | ||||
| Resistance 3 (R3) | 18.55 | 17.99 | 18.33 | ||
| Resistance 2 (R2) | 17.99 | 17.59 | 18.01 | 18.24 | |
| Resistance 1 (R1) | 17.50 | 17.34 | 17.75 | 17.55 | 18.16 |
| Pivot Point | 16.94 | 16.94 | 17.06 | 16.96 | 16.94 |
| Support 1 (S1) | 16.45 | 16.54 | 16.70 | 16.50 | 15.88 |
| Support 2 (S2) | 15.89 | 16.29 | 15.91 | 15.80 | |
| Support 3 (S3) | 15.40 | 15.89 | 15.71 | ||
| Support 4 (S4) | 15.45 |
